Global Gastroparesis Drugs Market 2017-2021
出 版 商：Technavio
出版日期：2017/05/03
頁 數：70頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
ABSTRACT
About Gastroparesis Drugs
Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. Normally, the vagus nerve controls the stomach muscles, which are responsible for the movement of food in the stomach. These muscles contract to break up the food and lead to its movement through the gastrointestinal tract. Gastroparesis can be caused due to the damage of vagus nerve by illness or injury. The disease does not have complete remission; however, proper medications along with the changes in diet can provide relief.
Technavio’s analysts forecast the global gastroparesis drugs market to grow at a CAGR of 3.54% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global gastroparesis drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Gastroparesis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Cadila Pharmaceuticals
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Valeant
Other prominent vendors
‧ Evoke Pharma
‧ Teva Pharmaceutical Industries
‧ Theravance Biopharma
Market driver
‧ Rising cases of diabetes fueling the prevalence of diabetic gastroparesis.
‧ For a full, detailed list, view our report
Market challenge
‧ Difficulty in diagnosis is hampering the medication process.
‧ For a full, detailed list, view our report
Market trend
‧ Introduction of novel ways for the treatment of gastroparesis symptoms.
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
About Gastroparesis Drugs
Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. Normally, the vagus nerve controls the stomach muscles, which are responsible for the movement of food in the stomach. These muscles contract to break up the food and lead to its movement through the gastrointestinal tract. Gastroparesis can be caused due to the damage of vagus nerve by illness or injury. The disease does not have complete remission; however, proper medications along with the changes in diet can provide relief.
Technavio’s analysts forecast the global gastroparesis drugs market to grow at a CAGR of 3.54% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global gastroparesis drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Gastroparesis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Cadila Pharmaceuticals
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Valeant
Other prominent vendors
‧ Evoke Pharma
‧ Teva Pharmaceutical Industries
‧ Theravance Biopharma
Market driver
‧ Rising cases of diabetes fueling the prevalence of diabetic gastroparesis.
‧ For a full, detailed list, view our report
Market challenge
‧ Difficulty in diagnosis is hampering the medication process.
‧ For a full, detailed list, view our report
Market trend
‧ Introduction of novel ways for the treatment of gastroparesis symptoms.
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
PART 05: Disease overview
PART 06: Market landscape
‧ Market overview
‧ Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by disease type
‧ Diabetic gastroparesis
‧ Idiopathic gastroparesis
‧ Others
PART 09: Market segmentation by drug class
‧ Prokinetic agents
‧ Antiemetic agents
‧ Botulinum toxin injection
PART 10: Geographical segmentation
‧ Gastroparesis drugs market in Americas
‧ Gastroparesis drugs market in EMEA
‧ Gastroparesis drugs market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 13: Market trends
‧ Fast track approvals and acquisitions to change the phase of the market
‧ Introduction of novel ways for the treatment of gastroparesis symptoms
PART 14: Vendor landscape
‧ Competitive scenario
‧ Cadila Pharmaceuticals
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Valeant
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Causes of gastroparesis
Exhibit 02: Major complications associated with gastroparesis
Exhibit 03: Diagnosis and treatment of gastroparesis
Exhibit 04: Global gastroparesis drugs market snapshot
Exhibit 05: Global gastroparesis drug market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global gastroparesis drugs market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline summary based on vendors
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global gastroparesis drugs market by disease type 2016
Exhibit 11: Global gastroparesis drugs market share by disease type 2016 (%)
Exhibit 12: Market snapshot: Global gastroparesis drugs market 2016-2021
Exhibit 13: Function of vagus nerves in digestive system
Exhibit 14: Global diabetic gastroparesis drugs market 2016-2021 ($ millions)
Exhibit 15: Global idiopathic gastroparesis drugs market 2016-2021 ($ millions)
Exhibit 16: Other causes of gastroparesis
Exhibit 17: Global gastroparesis drugs market by other causes 2016-2021 ($ millions)
Exhibit 18: Segmentation of global gastroparesis drug market by drug class
Exhibit 19: Market analysis of gastroparesis drug class
Exhibit 20: Global gastroparesis drugs market based on geography 2016 and 2021
Exhibit 21: Global gastroparesis drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 22: Market scenario in Americas
Exhibit 23: Gastroparesis drugs market in the Americas 2016-2021 ($ millions)
Exhibit 24: Top American countries with diabetic population range (millions)
Exhibit 25: Market scenario in EMEA
Exhibit 26: Gastroparesis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 27: Market scenario in APAC
Exhibit 28: Top Asian countries with diabetic population range (millions)
Exhibit 29: Gastroparesis drugs market in APAC 2016-2021 ($ millions)
Exhibit 30: New cases of diabetes by 2040
Exhibit 31: Possible treatments for gastroparesis.
Exhibit 32: Alternate treatment options for gastroparesis
Exhibit 33: Factors affecting the diagnosis of gastroparesis
Exhibit 34: Strategic success factors of companies in global gastroparesis drug market
Exhibit 35: Competitive structure analysis of global gastroparesis market
Exhibit 36: Cadila Pharmaceuticals: Key highlights
Exhibit 37: Cadila Pharmaceuticals: Strength assessment
Exhibit 38: Cadila Pharmaceuticals: Strategy assessment
Exhibit 39: Cadila Pharmaceuticals: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Valeant: Key highlights
Exhibit 49: Valeant: Strength assessment
Exhibit 50: Valeant: Strategy assessment
Exhibit 51: Valeant: Opportunity assessment
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
PART 05: Disease overview
PART 06: Market landscape
‧ Market overview
‧ Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by disease type
‧ Diabetic gastroparesis
‧ Idiopathic gastroparesis
‧ Others
PART 09: Market segmentation by drug class
‧ Prokinetic agents
‧ Antiemetic agents
‧ Botulinum toxin injection
PART 10: Geographical segmentation
‧ Gastroparesis drugs market in Americas
‧ Gastroparesis drugs market in EMEA
‧ Gastroparesis drugs market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 13: Market trends
‧ Fast track approvals and acquisitions to change the phase of the market
‧ Introduction of novel ways for the treatment of gastroparesis symptoms
PART 14: Vendor landscape
‧ Competitive scenario
‧ Cadila Pharmaceuticals
‧ GlaxoSmithKline
‧ Johnson & Johnson
‧ Valeant
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Causes of gastroparesis
Exhibit 02: Major complications associated with gastroparesis
Exhibit 03: Diagnosis and treatment of gastroparesis
Exhibit 04: Global gastroparesis drugs market snapshot
Exhibit 05: Global gastroparesis drug market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global gastroparesis drugs market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline summary based on vendors
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global gastroparesis drugs market by disease type 2016
Exhibit 11: Global gastroparesis drugs market share by disease type 2016 (%)
Exhibit 12: Market snapshot: Global gastroparesis drugs market 2016-2021
Exhibit 13: Function of vagus nerves in digestive system
Exhibit 14: Global diabetic gastroparesis drugs market 2016-2021 ($ millions)
Exhibit 15: Global idiopathic gastroparesis drugs market 2016-2021 ($ millions)
Exhibit 16: Other causes of gastroparesis
Exhibit 17: Global gastroparesis drugs market by other causes 2016-2021 ($ millions)
Exhibit 18: Segmentation of global gastroparesis drug market by drug class
Exhibit 19: Market analysis of gastroparesis drug class
Exhibit 20: Global gastroparesis drugs market based on geography 2016 and 2021
Exhibit 21: Global gastroparesis drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 22: Market scenario in Americas
Exhibit 23: Gastroparesis drugs market in the Americas 2016-2021 ($ millions)
Exhibit 24: Top American countries with diabetic population range (millions)
Exhibit 25: Market scenario in EMEA
Exhibit 26: Gastroparesis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 27: Market scenario in APAC
Exhibit 28: Top Asian countries with diabetic population range (millions)
Exhibit 29: Gastroparesis drugs market in APAC 2016-2021 ($ millions)
Exhibit 30: New cases of diabetes by 2040
Exhibit 31: Possible treatments for gastroparesis.
Exhibit 32: Alternate treatment options for gastroparesis
Exhibit 33: Factors affecting the diagnosis of gastroparesis
Exhibit 34: Strategic success factors of companies in global gastroparesis drug market
Exhibit 35: Competitive structure analysis of global gastroparesis market
Exhibit 36: Cadila Pharmaceuticals: Key highlights
Exhibit 37: Cadila Pharmaceuticals: Strength assessment
Exhibit 38: Cadila Pharmaceuticals: Strategy assessment
Exhibit 39: Cadila Pharmaceuticals: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Valeant: Key highlights
Exhibit 49: Valeant: Strength assessment
Exhibit 50: Valeant: Strategy assessment
Exhibit 51: Valeant: Opportunity assessment
